Helixmith

Helixmith Co., Ltd is a biotechnology company based in Seoul, South Korea, focused on discovering and developing biopharmaceuticals for various human diseases. The company has a diverse pipeline that includes novel biologics and herbal therapeutics targeting cardiovascular disease, cancer, and immune disorders. Its flagship product, VM202, is a DNA-based drug aimed at treating cardiovascular and neurological conditions. Helixmith’s pipeline also features VM206, a therapeutic cancer vaccine for HER2/neu positive breast or ovarian cancer, and VM501, a re-engineered interleukin 11 targeting chemotherapy-induced thrombocytopenia. The company is engaged in clinical studies in the United States, Korea, and China, with ongoing trials for several products, including VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. Originally founded as ViroMed Co., Ltd in 1996, the company rebranded to Helixmith Co., Ltd in April 2019.